Faculty, Staff and Student Publications
Publication Date
3-1-2025
Journal
Cancer Research Communications
Abstract
FOLR1 is heterogeneously overexpressed in epithelial ovarian cancer. We examined the combined effects of the anti-FOLR1 antibody-drug conjugate (IMGN853) with other drugs, including topotecan, anti-VEGF-A antibody, and olaparib. These findings could contribute to the continued development of IMGN853 in the treatment of ovarian cancer.
Keywords
Female, Humans, Ovarian Neoplasms, Autophagy, Immunoconjugates, Antineoplastic Combined Chemotherapy Protocols, Cell Line, Tumor, Piperazines, Carcinoma, Ovarian Epithelial, Topotecan, Folate Receptor 1, Phthalazines, Vascular Endothelial Growth Factor A, Animals, Mice
DOI
10.1158/2767-9764.CRC-24-0215
PMID
40029935
PMCID
PMC11951858
PubMedCentral® Posted Date
3-28-2025
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons